| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1025059525 |
| P356 | DOI | 10.1007/S00401-015-1399-Y |
| P932 | PMC publication ID | 4436687 |
| P698 | PubMed publication ID | 25720744 |
| P5875 | ResearchGate publication ID | 272836495 |
| P50 | author | Pieter Wesseling | Q42626526 |
| Jaap C Reijneveld | Q93118855 | ||
| P2093 | author name string | Thomas Wurdinger | |
| Myron G Best | |||
| Nik Sol | |||
| Sebastiaan Zijl | |||
| P2860 | cites work | A new look at cerebrospinal fluid circulation | Q21195862 |
| RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls | Q24594189 | ||
| Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers | Q24614672 | ||
| A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. | Q24631193 | ||
| A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion | Q24633772 | ||
| An integrated genomic analysis of human glioblastoma multiforme | Q24648860 | ||
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| Circulating microRNAs as stable blood-based markers for cancer detection | Q24652098 | ||
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| Circulating glioma biomarkers | Q26830329 | ||
| Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers | Q27023509 | ||
| MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 | ||
| An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. | Q27852141 | ||
| Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma | Q27852713 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases | Q28131780 | ||
| Serum YKL-40 following resection for cerebral glioblastoma | Q28253544 | ||
| Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy | Q28279046 | ||
| The somatic genomic landscape of glioblastoma | Q28300185 | ||
| Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas | Q28370451 | ||
| Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis | Q28484143 | ||
| Analysis of circulating tumor DNA to monitor metastatic breast cancer | Q29614797 | ||
| Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma | Q29615604 | ||
| Malignant gliomas in adults | Q29615708 | ||
| Detection of circulating tumor DNA in early- and late-stage human malignancies | Q29615778 | ||
| Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis | Q29619677 | ||
| Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA | Q29620083 | ||
| CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. | Q30402063 | ||
| A randomized trial of bevacizumab for newly diagnosed glioblastoma | Q30410163 | ||
| AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. | Q30490422 | ||
| Blood-based biomarkers for malignant gliomas | Q30625411 | ||
| Identification of apolipoprotein A-II in cerebrospinal fluid of pediatric brain tumor patients by protein expression profiling | Q30817570 | ||
| Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors | Q33193164 | ||
| Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers | Q33262334 | ||
| Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas | Q37395331 | ||
| Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer | Q37412311 | ||
| A neurocentric perspective on glioma invasion | Q37638128 | ||
| A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool | Q37641229 | ||
| AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development | Q37760644 | ||
| Molecular diagnostics of gliomas: the clinical perspective | Q37791463 | ||
| Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases | Q37824302 | ||
| The origins of glioma: E Pluribus Unum? | Q37847107 | ||
| Genetics and pharmacogenomics of diffuse gliomas | Q38044076 | ||
| Circulating tumor cells: liquid biopsy of cancer | Q38046735 | ||
| Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma | Q38051323 | ||
| Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? | Q38062793 | ||
| Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers | Q38084817 | ||
| Circulating biomarkers of CNS tumors: an update. | Q38095109 | ||
| Using the molecular classification of glioblastoma to inform personalized treatment | Q38151582 | ||
| Molecular analysis of circulating tumour cells-biology and biomarkers | Q38180320 | ||
| Clinical relevance of circulating cell-free microRNAs in cancer | Q38184908 | ||
| MGMT testing--the challenges for biomarker-based glioma treatment | Q38218848 | ||
| International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading | Q38225758 | ||
| Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: how to break a vicious cycle. | Q38277068 | ||
| Osteopontin and splice variant expression level in human malignant glioma: radiobiologic effects and prognosis after radiotherapy | Q38395521 | ||
| Hematogenous dissemination of glioblastoma multiforme. | Q38969869 | ||
| Exploratory investigation of eight circulating plasma markers in brain tumor patients | Q39319659 | ||
| Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma | Q39401205 | ||
| Skeletal spread of an anaplastic astrocytoma (WHO grade III) and preservation of histopathological properties within metastases. | Q39601710 | ||
| Proteomic Identification of Haptoglobin α2 as a Glioblastoma Serum Biomarker: Implications in Cancer Cell Migration and Tumor Growth | Q39658758 | ||
| Detection of IDH1 mutation in the plasma of patients with glioma | Q40066837 | ||
| BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. | Q40126434 | ||
| Serum GFAP is a diagnostic marker for glioblastoma multiforme | Q40155072 | ||
| Downregulation of miR-544 in tissue, but not in serum, is a novel biomarker of malignant transformation in glioma | Q42119044 | ||
| Tenascin in cerebrospinal fluid is a useful biomarker for the diagnosis of brain tumour | Q42173852 | ||
| Nontemplated nucleotide additions distinguish the small RNA composition in cells from exosomes | Q42186566 | ||
| No evidence of tumour cells in blood of patients with glioma | Q42937694 | ||
| Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network | Q43266785 | ||
| Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. | Q43605374 | ||
| Prognostic value of erythrocyte sedimentation rate and C-reactive protein in the blood of patients with glioma | Q43715694 | ||
| O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme | Q44396187 | ||
| Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. | Q44785670 | ||
| MGMT promoter methylation in plasma of glioma patients receiving temozolomide | Q45088198 | ||
| Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors | Q45101245 | ||
| A specific miRNA signature in the peripheral blood of glioblastoma patients | Q45256953 | ||
| Plasma levels of tissue inhibitor of matrix metalloproteinase-1 correlate with diagnosis and prognosis of glioma patients. | Q46030319 | ||
| Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma | Q46796397 | ||
| 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size | Q47355822 | ||
| Cerebrospinal fluid (vascular endothelial growth factor) and serologic (recoverin) tumor markers for malignant glioma | Q47577124 | ||
| Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme | Q47914088 | ||
| Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients | Q47956458 | ||
| New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. | Q47959541 | ||
| The stem cell marker prominin-1/CD133 on membrane particles in human cerebrospinal fluid offers novel approaches for studying central nervous system disease. | Q48014679 | ||
| Detection of tumor-derived DNA in cerebrospinal fluid | Q48101212 | ||
| Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma | Q48137961 | ||
| Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis | Q48173788 | ||
| Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group | Q48271471 | ||
| Cerebrospinal fluid ferritin in glioblastoma: evidence for tumor synthesis | Q48317066 | ||
| Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma | Q48329991 | ||
| Plasma MicroRNA-21 concentration may be a useful biomarker in glioblastoma patients | Q48409555 | ||
| Neuro-oncology: a step towards clinical blood biomarkers of glioblastoma | Q48467746 | ||
| Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis | Q48520992 | ||
| Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma | Q48523844 | ||
| Plasma fibronectin in patients with brain tumors | Q48526185 | ||
| Plasma miR-454-3p as a potential prognostic indicator in human glioma | Q48563610 | ||
| Circulating endothelial progenitor cells in malignant gliomas | Q48573661 | ||
| Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome | Q48573837 | ||
| Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma | Q48584168 | ||
| Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma | Q48595349 | ||
| Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma | Q48616807 | ||
| Decrease in circulating endothelial progenitor cells in treated glioma patients. | Q48651060 | ||
| Angiogenic factors in plasma of brain tumour patients | Q48682956 | ||
| Neurospecific proteins in the serum of patients with brain tumors | Q48717903 | ||
| p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas | Q48728141 | ||
| Blood platelets contain tumor-derived RNA biomarkers | Q48954046 | ||
| Phenotypical analysis, relation to malignancy and prognostic relevance of ICOS+T regulatory and dendritic cells in patients with gliomas | Q48975027 | ||
| Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials | Q33288097 | ||
| Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris | Q33332841 | ||
| Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide | Q33335220 | ||
| First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia | Q33360637 | ||
| Platelets actively sequester angiogenesis regulators | Q33387520 | ||
| Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide | Q33391770 | ||
| Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme | Q33493013 | ||
| Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma | Q33530811 | ||
| Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status | Q33616627 | ||
| Prognostic significance of serum alpha 1-acid glycoprotein in patients with glioblastoma multiforme: a preliminary communication | Q33621360 | ||
| Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies | Q33925544 | ||
| Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma | Q33990834 | ||
| Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay | Q34089398 | ||
| Cerebrospinal fluid and plasma biomarkers in Alzheimer disease | Q34098866 | ||
| Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades | Q34132740 | ||
| Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas | Q34132959 | ||
| Cell-free nucleic acids as biomarkers in cancer patients | Q34184393 | ||
| Pitfalls in the measurement of circulating vascular endothelial growth factor | Q34198458 | ||
| Insights into pediatric diffuse intrinsic pontine glioma through proteomic analysis of cerebrospinal fluid | Q34228023 | ||
| Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. | Q34278191 | ||
| Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas | Q34279430 | ||
| Liquid biopsy: monitoring cancer-genetics in the blood | Q34356149 | ||
| Brain tumor cells in circulation are enriched for mesenchymal gene expression | Q34458631 | ||
| Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor | Q34480501 | ||
| High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34620657 | ||
| Extracellular vesicles as prospective carriers of oncogenic protein signatures in adult and paediatric brain tumours | Q34625129 | ||
| Biomarkers of response and resistance to antiangiogenic therapy | Q34673567 | ||
| Circulating endothelial cells and procoagulant microparticles in patients with glioblastoma: prognostic value. | Q34902070 | ||
| Cancer micrometastases | Q34978121 | ||
| Identification of diagnostic serum protein profiles of glioblastoma patients | Q34981475 | ||
| Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan | Q34999120 | ||
| MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development | Q35036059 | ||
| IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection | Q35059157 | ||
| Evaluation of eight plasma proteins as candidate blood-based biomarkers for malignant gliomas | Q35067781 | ||
| Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors. | Q51990859 | ||
| Application of immunosignatures to the assessment of Alzheimer's disease. | Q53427707 | ||
| Inactivation of O6-alkylguanine-DNA alkyltransferase in HeLa cells by cisplatin. | Q53513489 | ||
| Immunosuppressive acidic protein in patients with brain tumours: a preliminary report. | Q54065459 | ||
| Larger companies dominate cancer companion diagnostic approvals. | Q54551332 | ||
| Detection of serum Alu element hypomethylation for the diagnosis and prognosis of glioma. | Q55461647 | ||
| Prognostic value of plasma d-dimer levels in patients with glioblastoma multiforme - Results from a pilot study. | Q55463292 | ||
| Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients. | Q55463617 | ||
| Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy. | Q55463985 | ||
| Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. | Q55466614 | ||
| Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. | Q55467627 | ||
| YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. | Q55469339 | ||
| Serum levels of S-100B protein and neuron-specific enolase in glioma patients: a pilot study. | Q55471966 | ||
| Serum concentrations of soluble interleukin-2 receptor in patients with malignant brain tumors. | Q55474976 | ||
| Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and plasma thrombomodulin levels in glioblastoma patients. | Q55476209 | ||
| Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma. | Q55482583 | ||
| Free DNA in the serum of cancer patients and the effect of therapy. | Q55492005 | ||
| Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease | Q73759055 | ||
| Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas | Q80338347 | ||
| Measurement of matrix metalloproteinases in serum of patients with melanoma: snarled in technical pitfalls | Q80404818 | ||
| High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas | Q81002518 | ||
| Primary brain tumours in adults | Q83911864 | ||
| Microfluidic isolation and transcriptome analysis of serum microvesicles | Q35106801 | ||
| Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept | Q35115634 | ||
| Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas | Q35419401 | ||
| Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma. | Q35586677 | ||
| Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma | Q35633805 | ||
| Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma | Q35633850 | ||
| An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme | Q35800650 | ||
| Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma | Q35914541 | ||
| Platelets and platelet-like particles mediate intercellular RNA transfer | Q36058568 | ||
| MicroRNAs in body fluids--the mix of hormones and biomarkers | Q36176435 | ||
| Metabolomics of human cerebrospinal fluid identifies signatures of malignant glioma | Q36208989 | ||
| Validation of new biomarkers in systemic autoimmune diseases | Q36231859 | ||
| Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice | Q36344709 | ||
| Epigenetic biomarkers of T-cells in human glioma. | Q36484129 | ||
| Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma | Q36560956 | ||
| Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage | Q36579481 | ||
| Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. | Q36673354 | ||
| GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients. | Q36798779 | ||
| Diffuse glioma growth: a guerilla war | Q36931690 | ||
| Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients | Q36935622 | ||
| Molecular genetic markers as predictors of response to chemotherapy in gliomas | Q36956110 | ||
| Cytokine patterns in brain tumour progression | Q36999339 | ||
| Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas | Q37023701 | ||
| Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients | Q37039354 | ||
| Brain metastasis from an unknown primary, or primary brain tumour? A diagnostic dilemma | Q37102055 | ||
| The evolution of our understanding on glioma | Q37120960 | ||
| Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. | Q37340643 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P304 | page(s) | 849-865 | |
| P577 | publication date | 2015-02-27 | |
| P1433 | published in | Acta Neuropathologica | Q343168 |
| P1476 | title | Liquid biopsies in patients with diffuse glioma | |
| P478 | volume | 129 |
| Q48239891 | A novel all-in-one intraoperative genotyping system for IDH1-mutant glioma. |
| Q28073765 | Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer |
| Q38586617 | Circulating biomarkers for gliomas |
| Q91012634 | Circulating biomarkers in patients with glioblastoma |
| Q37687613 | Circulating tumor cell is a common property of brain glioma and promotes the monitoring system |
| Q92864393 | Clinical implications of intratumor heterogeneity: challenges and opportunities |
| Q26774502 | Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence |
| Q26796208 | Current Understanding of Circulating Tumor Cells - Potential Value in Malignancies of the Central Nervous System |
| Q37702107 | DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients. |
| Q40291585 | Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. |
| Q38591062 | Emerging circulating biomarkers in glioblastoma: promises and challenges. |
| Q38845041 | Glial biomarkers in human central nervous system disease |
| Q92154901 | Identification of Astrocytoma Blood Serum Protein Profile |
| Q92454918 | Liquid Biopsy as a Tool for Differentiation of Leiomyomas and Sarcomas of Corpus Uteri |
| Q91845076 | Measure Twice: Promise of Liquid Biopsy in Pediatric High-Grade Gliomas |
| Q64074719 | Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas |
| Q90462003 | New Frontiers in Diagnosis and Therapy of Circulating Tumor Markers in Cerebrospinal Fluid In Vitro and In Vivo |
| Q27002448 | Oligodendroglioma: pathology, molecular mechanisms and markers |
| Q52584624 | Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. |
| Q26749972 | Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen |
| Q100995148 | Tumor-Educated Platelet RNA for the Detection and (Pseudo)progression Monitoring of Glioblastoma |
| Q64319932 | Ultracentrifugation versus kit exosome isolation: nanoLC-MS and other tools reveal similar performance biomarkers, but also contaminations |
Search more.